BERGENBIO ANNOUNCES COMPLETE DATA ANALYSIS OF ACCORD2 PHASE II BEMCENTINIB STUDY IN HOSPITALIZED COVID-19 PATIENTS - PRIMARY EFFICACY ENDPOINT MET ...Middle East

Complete data analysis confirms that the primary endpoint of improved clinical response and key secondary endpoints were met in a subprotocol under the platform ACCORD2 study where bemcentinib was added to standard of care therapy BerGenBio to confirm the ACCORD2 data by progressing...

Hence then, the article about bergenbio announces complete data analysis of accord2 phase ii bemcentinib study in hospitalized covid 19 patients primary efficacy endpoint met was published today ( Tuesday 26/04/2022 - 08:43 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( BERGENBIO ANNOUNCES COMPLETE DATA ANALYSIS OF ACCORD2 PHASE II BEMCENTINIB STUDY IN HOSPITALIZED COVID-19 PATIENTS - PRIMARY EFFICACY ENDPOINT MET )

Also on site :

• ‘The Sun Never Sets’ Review: Dakota Johnson and Jake Johnson Bring Warm Chemistry to Joe Swanberg’s Wishy-Washy Romantic Dramedy
• Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
• How Boston Blue's St. Patrick's Day Episode Ties Back To Linda Reagan's Blue Bloods Death — Plus, Jamie And Eddie's Baby Boy Revealed